Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | MMP1 | P03956 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15145822 | 0.93 | SMN1; SMN2 (0.78) | MEP1BSMN1; SMN2LMNAMMP1MEN1 | |
| SCHEMBL15145807 | 0.93 | SMN1; SMN2 (0.74) | MEP1BSMN1; SMN2LMNAMMP1MEN1 | |
| SCHEMBL9487015 | 0.92 | ALDH1A1 (0.69) | MEP1BSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL16265637 | 0.89 | MEN1 (0.66) | MEP1BSMN1; SMN2LMNAMMP1MEN1 | |
| SCHEMBL12617210 | 0.88 | MEP1B (0.64) | MEP1BSMN1; SMN2LMNAMMP1MEN1 | |
| SCHEMBL15145830 | 0.82 | MEP1B (0.56) | MEP1BLMNAMMP1MEN1KMT2A | |
| SCHEMBL11708062 | 0.82 | MEP1B (0.68) | MEP1BSMN1; SMN2LMNAMMP1MEN1 | |
| SCHEMBL7675070 | 0.80 | PRMT1 (0.68) | LMNAMEN1KMT2AALDH1A1POLB | |
| Benzene SCHEMBL16265417 | 0.79 | ALDH1A1 (0.56) | SMN1; SMN2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL12359429 | 0.79 | SMN1; SMN2 (0.80) | SMN1; SMN2LMNAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216954-B2 | Serine racemase inhibitor | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2015-12-22 | — | — | US | disclosed |
| US-9216954-B2 | Serine racemase inhibitor | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2015-12-22 | — | — | US | disclosed |
| US-20140371291-A1 | SERINE RACEMASE INHIBITOR | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371291-A1 | SERINE RACEMASE INHIBITOR | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2014-12-18 | — | — | US | disclosed |
| EP-2808014-A1 | SERINE RACEMASE INHIBITOR | National University Corporation University Of Toyama (JP) | 2014-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371291-A1 | SERINE RACEMASE INHIBITOR | SRR, PRSS1, ME1 | MEP1B 230/4885SMN1; SMN2 967/4885LMNA 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.